Comparing the Effect of Vaginal Misoprostol With Dinoprostone in Term Pregnancies

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2007 by Hormozgan University of Medical Sciences.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Hormozgan University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT00432588
First received: February 6, 2007
Last updated: May 31, 2007
Last verified: February 2007
  Purpose

Hypothesis (H0): Labor duration and obstetric complications are not significantly different in the three groups (misoprostol-dinoprostone-oxytocin).


Condition Intervention Phase
Preeclampsia
Fetal Death
Fetal Membranes, Premature Rupture
Drug: misoprostol
Drug: dinoprostone
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Hormozgan University of Medical Sciences:

  Eligibility

Genders Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • Term pregnancy
  • Singleton
  • Vertex
  • Bishop score below 6

Exclusion Criteria:

  • History of drug reaction
  • Medical disease
  • IUGR
  • Oligohydramnios
  • Vaginal bleeding
  • Fetal anomaly
  • Uterine scar
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00432588

Locations
Iran, Islamic Republic of
Shariaty Maternity Hospital Not yet recruiting
Tehran, Iran, Islamic Republic of
Contact: Mitra Ahmad Soltani, MD    0098 021 22301004    m_a_sol@yahoo.com   
Sponsors and Collaborators
Hormozgan University of Medical Sciences
Investigators
Principal Investigator: Mitra Ahmad Soltani Hormozgan University of Medical Sciences
Study Chair: Minoo Rajaee Lari, Perinatologist - Obs and Gyn Department of Obs and Gyn - HUMS
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00432588     History of Changes
Other Study ID Numbers: Misoprostol vs Dinoprostone
Study First Received: February 6, 2007
Last Updated: May 31, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Hormozgan University of Medical Sciences:
IUFD
POSTTERM
ROM

Additional relevant MeSH terms:
Fetal Death
Fetal Membranes, Premature Rupture
Pre-Eclampsia
Rupture
Pregnancy Complications
Death
Pathologic Processes
Obstetric Labor Complications
Hypertension, Pregnancy-Induced
Wounds and Injuries
Dinoprostone
Misoprostol
Oxytocics
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Anti-Ulcer Agents
Gastrointestinal Agents

ClinicalTrials.gov processed this record on August 21, 2014